Roswell Park appoints immuno-oncology chief
Click Here to Manage Email Alerts
Pawel Kalinski, MD, PhD, has been promoted to Jacobs family endowed chair of immunology at Roswell Park Comprehensive Cancer Center.
Kalinski also will serve as chief of the division of translational immuno-oncology and senior vice president for team science.
Kalinski — who joined the Roswell Park staff in 2017 — previously served as vice chair for translational research, director of cancer vaccine and dendritic cell therapies, Rustum family endowed professor for molecular therapeutics and translational research, and co-leader of the tumor immunology and immunotherapy program.
Kalinski’s interests include the biology of dendritic cells and dendritic cell vaccines, the biology of T cells and T-cell targeting therapies, the biology of natural killer cells and human myeloid-derived suppressor cells, and the regulation of chemokine production in the tumor microenvironment.
“The work Dr. Kalinski leads is stunning in its scope, its uniqueness, and its potential for improving patient care and survival,” Candace S. Johnson, PhD, president and CEO of Roswell Park, said in a press release. “We look forward to seeing all that he will accomplish and the achievements he will inspire our team to realize.”
Read more about
Click Here to Manage Email Alerts